Background <p>In this study, we investigated the correlation between the mutation rates for <i>ampC</i> derepression and species or <i>ampC</i> genotypes in <i>Enterobacter cloacae</i> complex (ECC) susceptible to ceftriaxone. Non-duplicate ceftriaxone-sensitive ECC isolates (90) were obtained from September 2021 to January 2023 at Ruijin Hospital, Shanghai. <i>hsp60</i> genotyping and PCR were used for species and <i>ampC</i> identification, respectively. Thirteen strains with the negative <i>ampC</i> amplification results were sequenced, and the mutation rates for <i>ampC</i> derepression were determined by performing Luria–Delbrück fluctuation analyses.</p> Results <p> <?tk 3?>Among these isolates, <i>E. hormaechei</i> was the most prevalent (54.44%), followed by <i>E. roggenkampii</i> (12.22%), <i>E. cloacae</i> (11.11%), <i>E. bugandensis</i> (10.00%), <i>E. asburiae</i> (4.44%), and <i>E. kobei</i> (4.44%). For <i>E. ludwigii</i>, <i>E. mori</i>, and <i>E. sichuanensis</i>, only a single strain was identified. There were 72 strains with <i>bla</i><sub>ACT</sub>, 13 with <i>bla</i><sub>MIR</sub>, and five with <i>bla</i><sub>CMH</sub>. The <i>ampC</i>-derepressed mutation rate was (2.25 ± 1.81) × 10<sup>−8</sup> for <i>E. asburiae</i>, (3.21 ± 2.96) × 10<sup>−8</sup> for <i>E. bugandensis</i>, (6.06 ± 11.95) × 10<sup>−8</sup> for <i>E. cloacae</i>, (1.12 ± 3.44) × 10<sup>−7</sup> for <i>E. hormaechei</i>, (7.76 ± 11.41) × 10<sup>−8</sup> for <i>E. kobei</i>, (3.99 ± 9.65) × 10<sup>−8</sup> for <i>E. roggenkampii</i>, 5.87 × 10<sup>−8</sup> for <i>E. ludwigii</i>, 1.12 × 10<sup>−7</sup> for <i>E. mori</i>, and 2.17 × 10<sup>−7</sup> for <i>E. sichuanensis.</i> The mutation rate was (8.94 ± 28.61) × 10<sup>−8</sup> for <i>bla</i><sub>ACT</sub>, (2.62 ± 2.16) × 10<sup>−8</sup> for <i>bla</i><sub>CMH</sub>, and (8.10 ± 13.84) × 10<sup>−8</sup> for <i>bla</i><sub>MIR</sub>.</p> Conclusions <p>ECC was found to have high mutation rate−inducible AmpC production with no species or <i>ampC</i> genotype differences. This highlights an important clinical concern, i.e., the high risk of treatment failure with third-generation cephalosporins in individuals with inducible AmpC-containing ECC.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Correlation between the mutation rates for ampC derepression and species or ampC genotypes in Enterobacter cloacae complex

  • Lianyan Xie,
  • Yanrong Wu,
  • Qiulan Huang,
  • Jingyong Sun

摘要

Background

In this study, we investigated the correlation between the mutation rates for ampC derepression and species or ampC genotypes in Enterobacter cloacae complex (ECC) susceptible to ceftriaxone. Non-duplicate ceftriaxone-sensitive ECC isolates (90) were obtained from September 2021 to January 2023 at Ruijin Hospital, Shanghai. hsp60 genotyping and PCR were used for species and ampC identification, respectively. Thirteen strains with the negative ampC amplification results were sequenced, and the mutation rates for ampC derepression were determined by performing Luria–Delbrück fluctuation analyses.

Results

Among these isolates, E. hormaechei was the most prevalent (54.44%), followed by E. roggenkampii (12.22%), E. cloacae (11.11%), E. bugandensis (10.00%), E. asburiae (4.44%), and E. kobei (4.44%). For E. ludwigii, E. mori, and E. sichuanensis, only a single strain was identified. There were 72 strains with blaACT, 13 with blaMIR, and five with blaCMH. The ampC-derepressed mutation rate was (2.25 ± 1.81) × 10−8 for E. asburiae, (3.21 ± 2.96) × 10−8 for E. bugandensis, (6.06 ± 11.95) × 10−8 for E. cloacae, (1.12 ± 3.44) × 10−7 for E. hormaechei, (7.76 ± 11.41) × 10−8 for E. kobei, (3.99 ± 9.65) × 10−8 for E. roggenkampii, 5.87 × 10−8 for E. ludwigii, 1.12 × 10−7 for E. mori, and 2.17 × 10−7 for E. sichuanensis. The mutation rate was (8.94 ± 28.61) × 10−8 for blaACT, (2.62 ± 2.16) × 10−8 for blaCMH, and (8.10 ± 13.84) × 10−8 for blaMIR.

Conclusions

ECC was found to have high mutation rate−inducible AmpC production with no species or ampC genotype differences. This highlights an important clinical concern, i.e., the high risk of treatment failure with third-generation cephalosporins in individuals with inducible AmpC-containing ECC.